Thrilled to have this finally published! If you are interested in learning about the collagen IV diseases Gould syndrome and Alport syndrome, add this to your reading list. www.nature.com/articles/s41...

🧬Introducing our first-ever handbook of genetic nephrology, with free download until 8/2025 authors.elsevier.com/a/1lSgWzcYo6... @andrewmallett8.bsky.social and I saw a gap in foundational reading of genetic nephrology and decided to gather articles that clinician and learners can all enjoy

We got it 💪🏻 #ERA25 thank you @rosertorra.bsky.social 👏🏻

Finding novel antigens in membranous nephropathy through mass spectrometry by @johannmorelle.bsky.social #ERA25

The first #ERA25 simultaneous pub CONFIDENCE trial of empagliflozin + finerenone in N = 579 Greater reduction in ACR and BP Note the impressive GFR dip www.nejm.org/doi/full/10....

Congrats to all the @asnkidney.bsky.social lifetime and mid-career awardees! @ksusztak.bsky.social @genetickidneydoc.bsky.social @shinamenon.bsky.social @michellejtx.bsky.social and everyone else!

Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy bit.ly/4ccCs4H #OpenAccess #VisualAbstract

Complement activation in secondary thrombotic microangiopathies doi.org/10.1093/ndt/... 👉This review summarizes the current understanding and future directions in the management of secondary TMA, emphasizing the potential of complement inhibition as therapeutic strategy

Secondary #TMA represent a major unmet medical need. Grateful for the opportunity to review the role of #complement and discuss when to consider complement inhibitors in these dramatic diseases. 🙏 to outstanding co-authors and the #ERA IWG @kronbichlerlab.bsky.social @ndt-era.bsky.social

Today "a milestone in the evolution of personalized therapies for rare & ultra-rare inborn errors of metabolism" —the 1st human to undergo custom genome editing —from decades of NIH funded research www.nejm.org/doi/full/10.... @nejm.org www.nejm.org/doi/full/10.... www.nytimes.com/2025/05/15/h...

Beautiful essay from Rajeev Raghavan in the @nejm.org Driving Jackson (a dialysis patient to his clinic appointments) www.nejm.org/doi/full/10.... #NephSky

In an article within the #ASNJASN series, Mechanisms of Kidney Diseases, authors examine the link between gold salts, penicillamine, and mercury and membranous nephropathy, aiming to develop new hypotheses on how these substances may promote immune dysregulation. https://bit.ly/JASN0719

The whole story is surreally fascinating Tim Friede’s YT channel: youtube.com/@timfriede57... The @cellpress.bsky.social paper: www.cell.com/cell/fulltex... A BBC story www.bbc.com/news/article... A universal antivenom would be huge - this seems like a big step

Some take home messages from an inspiring talk by @nephrorock.bsky.social at @kidneycon.bsky.social !

🔥 Happening tonight #nephjc

🔥 Final (pdf) version available online (free): Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy @ajkd.bsky.social ➡️ doi.org/10.1053/j.aj... #OpenAccess 🙏 to all collaborators and sponsors!

In the Advance-HTN phase 2b trial of the aldosterone synthase inhibitor lorundrostat in participants with uncontrolled hypertension, lorundrostat was associated with greater reductions in blood pressure than placebo. Full trial results: nej.md/4ipbCIf #MedSky #CardioSky

The ASIs have arrived www.nejm.org/doi/full/10.... Aldosterone synthase inhibitors - first one to finish the phase 3 line #Lorundrostat #Hypertension

Why you should know your viral exposure status (i.e CMV) if you're going to undergo immunotherapy for cancer (but almost no one knows) www.nature.com/articles/s41...

EKFC equation to estimate GFR from creatinine and cystatin C, you freely use this link ekfccalculator.pages.dev

Sparsentan as First-Line Treatment of Incident Patients with IgAN: Interim Analysis of the SPARTAN Trial #Nephpearls #NKFClinicals 🇺🇸 #NephSky 📌 The rapid reduction of u-sCD163 levels is the first demonstration of SPAR’s anti-inflammatory effect in humans and supports preclinical data

DUPLEX Posthoc: Antiproteinuric and nephroprotective benefits of Sparsentan in patients with FSGS #Nephpearls #NKFClinicals 🇺🇸 #NephSky

PARASOL ☂️: Achieving proteinuria <0.7 g/g is associated with meaningful reduction in kidney failure risk in FSGS #Nephpearls #NKFClinicals #NephSky

Sparsentan (DEARA) and FSGS #Nephpearls #NKFClinicals #NephSky

Ultra rapid prednisone taper (median 14 days!) in ANCA vasculitis from the Imperial group www.kireports.org/article/S246... in @kireports.bsky.social #NephSky

The FDA approved inebilizumab-cdon (UPLIZNA; @Amgen as the first and only treatment for adult patients diagnosed with immunoglobulin G4-related disease (IgG4-RD). #RareDiseases pubmed.ncbi.nlm.nih.gov/39969992/

Interesting paper @asnpublications.bsky.social ​SGLT2 inhibitors prevent kidney magnesium loss caused by cisplatin #flozins improve Mg reabsorption in the thick ascending limb and distal convoluted tubule VA by @corinateodosiu.bsky.social #nephsky #medsky journals.lww.com/jasn/abstrac...

Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy bit.ly/4ccCs4H #OpenAccess #VisualAbstract

Grateful for the opportunity to work with such a team — to expand the original technique of laser capture microdissection and mass spectrometry for the identification of target antigens in membranous nephropathy ✨

Oral Ozempic reduced major adverse cardiovascular events in a large randomized trial of 9,650 participants with T2 diabetes and high-risk @nejm.org #ACC25 www.nejm.org/doi/full/10....

FRESH-UP Trial #ACC25 #medsky RCT comparing liberal vs restricted fluid intake (≤1500 ml/d) in 504 pts with stable chronic HF 🌊No difference in status health quantified by Kansas City Cardiomyopathy Questionnaire at 3 mths 🌊 More thirst distress with restriction www.nature.com/articles/s41...

People look at this and scream about getting an AV accesses because of the dramatically lower infection rate, but 1.2 infections per 100 patient-years is 1.2 blood stream infections per patient per 8.8 years We have bigger fish to fry in dialysis than one BSI per decade.

congrats to Novartis for receiving FDA approval for iptacopan for C3G. What an amazing era to start having therapies www.novartis.com/news/media-r...

"In labs around the world, scientists are using A.I. to search among existing medicines for treatments that work for rare diseases." And saving some lives. @davidfajgenbaum.bsky.social gift link www.nytimes.com/2025/03/20/w...

Nice to see this in print - combined analysis of #CureGN and #CRIC demonstrates the value of broad family history collection from patients with various forms of CKD. Interestingly, positive family history of diabetes was associated with a higher risk of CKD progression even in non-diabetics!

www.era-online.org/publications... #podocytepuzzles

The Utility of Myeloperoxidase Immunostaining to Characterize Immune Deposits in Patients with Crescentic #Glomerulonephritis #nephsky www.kireports.org/article/S246...

Multiple sclerosis requires Epstein-Barr virus infection as an underpinning, exhibits self-directed antibodies to EBNA1, the virus's nuclear antigen, representing molecular mimicry. This combines with/ genetic risk factors (Figure, compared w/healthy controls) @pnas.org www.pnas.org/doi/epub/10....

1/ Thrilled to share our latest work ‘Mass Spectrometry with Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy’, just published in @ajkd.bsky.social www.ajkd.org/article/S027... #CHUUCLNamur #deDuveInstitute @inserm.fr #UCLouvain #CuSL A thread

People who can’t handle criticism are unfit to lead. Weak leaders fear dissent as a threat to their power. They silence their critics to shield their egos. Strong leaders welcome dissent as an opportunity for growth. They silence their egos to learn from their critics.

Research support for rare diseases, which cumulatively affect ~30 million Americans, is primarily derived from NIH. Such work is exemplified by Prof Anna Greka @broadinstitute.org in a new Ground Truths podcast. Open-access, w/ transcript, video, no ads erictopol.substack.com/p/anna-greka...

Mass Spectrometry With Data-Independent Acquisition for the Identification of Target Antigens in Membranous Nephropathy #nephsky www.ajkd.org/article/S027...

So maybe we don’t need to hold flozins before surgery after all? jamanetwork.com/journals/jam...

📢 Check out the final report from the KDIGO CKD-MBD Controversies Conference, published in the March issue of Kidney International! Explore key insights on osteoporosis, vascular calcification, and cardiovascular disease in CKD. 🔗 Read the report in KI: kdigo.co/2025-CKD-MBD... #CKDMBD

#Bartonella #Endocarditis-Associated #Glomerulonephritis: A Mimicker of Autoimmunity and Vasculitis #VisualAbstract by @krithicism www.kireports.org/ar...

In the ACCOLADE trial, avacopan, a complement C5a receptor antagonist, failed to reduce disease activity index in patients with C3 glomerulopathy @asnpublications.bsky.social journals.lww.com/jasn/fulltex...

Novel autoantibodies in autoimmune podocytopathies? @asnpublications.bsky.social journals.lww.com/jasn/fulltex...

Francis Collins, the NIH Director for 12 years, led the Human Genome Project and other NIH efforts for 32 years, resigned today. Key words from his resignation letter www.nytimes.com/2025/03/01/u...

Globally, 150+ rare kidney diseases affect 60–80 people per 100,000. Many are hereditary, with inherited kidney disease seen in 10% of adults & most children on #KRT. Yet, barriers to diagnosis & treatment persist, especially in LMICs. On #RareDiseaseDay, we call for action! #KidneyHealthMatters

The proof is in the data: academic.oup.com/ndt/advance-... Cysts are not caused by Alport syndrome, though patients with Alport syndrome can have cysts.